Similar Papers

Paper Title
Journal
Date
Author
PCN253 - Oncology Products in the Amnog Process – Learnings for a Successful Dossier Submission
J Dehnen ... K Goldhagen
Value in Health | VOL. 17
J Dehnen, et. al.J Dehnen ... K Goldhagen
26 Oct 2014
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.
...
Journal of Clinical Oncology | VOL. 41
, et. al. ...
01 Jun 2023
Decitabine Improves Outcomes in Older Patients with AML and Higher Blast Counts
Tapan Kadia ... Christopher Arthur
Clinical Lymphoma Myeloma and Leukemia | VOL. 15
Tapan Kadia, et. al.Tapan Kadia ... Christopher Arthur
01 Jun 2015
Abstract P1-18-11: Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3) trial
Michelino De Laurentiis ... Cristian Villanueva
Cancer Research | VOL. 82
Michelino De Laurentiis, et. al.Michelino De Laurentiis ... Cristian Villanueva
15 Feb 2022
View more papers

More From: Value in Health

Paper Title
Journal
Date
Author
Table of Contents
-
Value in Health | VOL. 28
--
01 Feb 2025
Cost-effectiveness of a digitally supported care management program for caregivers of people with dementia
Michelle Pfaff ... Bernhard Michalowsky
Value in Health | VOL. -
Michelle Pfaff, et. al.Michelle Pfaff ... Bernhard Michalowsky
01 Feb 2025
Editorial Board
-
Value in Health | VOL. 28
--
01 Feb 2025
How do individuals value worse-than-dead EQ-5D-5L health states in composite time trade-off tasks? A qualitative study
Meixia Liao ... Nan Luo
Value in Health | VOL. -
Meixia Liao, et. al.Meixia Liao ... Nan Luo
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.